FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

ALKEM Consensus Forecast

No. of reports in last year
3
No. of analysts
2
Average Consensus Forecast
2417.67
Consensus Potential
-16.17%

ALKEM Price Target Potential

BrokerageTargetPotential
HDFC Securities2650-5.31%
Ashika Stock Broking2423-15.18%

ALKEM Targets in FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for ALKEM
0% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

ALKEM Ratings

Long term ALKEM rating by FrontPage users
5/5 (1 Ratings)

3 ALKEM share price target reports by brokerages below. See what is analyst's view on ALKEM share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. ALKEM Forum
  3. ALKEM Price Target

ALKEM Share Price Target

ALKEM Share Price Target - Broker Reports - 2020

6-Jan-20
Price @ Call: 2089.44
Target: 2650
BUY
Last year, Alkem’s India business faced multiple headwinds including the ban on certain Fixed Dose Combinations (FDCs), a relatively weak anti-infective season and a slow growth in their trade generic business. However, on the positive side, the company’s chronic business continued to grow significantly ahead of the market growth rate, leading to improvements in its market share and ranking in therapy segments of CNS, anti-diabetic, cardiology and dermatology. International Business mainly led by the US, delivered a robust performance on the back of new product launches and market share gains in the company’s existing products. Alkem has more than 120 ANDAs filed with the US FDA and own front end to distribute and market its products. Alkem is amongst the top 10 pharmaceutical companies in India and during last fiscal, it outperformed the India Pharmaceutical Market (IPM) with growth of 14.3% compared to IPM growth of 10.5%. We expect 13% cagr in revenues on the back of 15% growth in US business and 13% cagr in India business over FY19-21E. Strong revenues and steady margin expansion and lower tax rate would lead to robust growth in PAT; estimate 25% PAT cagr over the same period. We recommend buy on Alkem Labs at CMP of Rs 2095 and add on dips to Rs 1965 for sequential price target of Rs 2380 and Rs 2650 over the next four quarters. The stock trades at ~21x FY21E earnings and we have arrived to sequential TP of Rs 2380 and Rs 2650 based upon 24x and 26.5x FY21E earnings respectively.
... Read more
6-Jan-20
Price @ Call: 2100
Target: 2423
BUY
We like Alkem due to near to mid term growth visibility, improving profitability, recovering return ratios, and growing free cash flows. Currently it trades at 19.3x/17.3x FY21E/FY22E EPS which is >25% discount to its historical multiple. We value Alkem at 20x FY22E EPS, recommend buy with target price Rs2,423.
... Read more

ALKEM Share Price Target - Broker Reports - 2019

14-Aug-19
Price @ Call: 1773.72
Target: 2180
BUY
On recovery path. We maintain BUY on ALKEM despite a big miss on our 1QFY20 estimates. Our TP is 2,180 (22x FY21E EPS) with estimates largely unchanged owing to a sharp recovery expected in the next two quarters following a shift in the seasonally strong quarters (from 1Q earlier to 2Q now). With a lower than expected impact of gMycophenolate competition in the US, coupled with the highest top-line growth in India business among large-cap peers (1QFY20), we maintain our FY20/21E revenue estimates for Alkem and model a 13% CAGR over FY19-21E. The profitability, too, is likely to expand by 100-120bps YoY with lower raw material prices and improving business mix. With moderated tax expectations, we model 25% EPS CAGR over FY19-21E. Alkem remains among the fastest-growing companies in the Indian market while its performance in the US also stands out. At CMP, Alkem is available at 18x FY21E EPS. Considering its stable branded business, healthy cashflows (~Rs 8bn annual FCFF over FY20/21E), and reasonable return ratios (22% RoIC in FY21E), we believe this is unjustified.
... Read more
30-May-19
Price @ Call: 1776.06
Target: 2050
BUY
We expect the stock to command premium over its peers owing to higher exposure to India business. Cutting down our earnings by 21% for FY21E to factor in lower growth in India business and EBITDA margin pressure and rolling over our earnings estimates to FY21E, we maintain our BUY recommendation on the stock with a revised Target Price of Rs2,050.
... Read more
27-Mar-19
Price @ Call: 1769
Target: 2170
BUY
We lower ALKEM’s P/E multiple to 22x (from 24x earlier) to factor in the increased competition in the US generics space and gradual downtrend in the domestic formulation industry. We arrive at PT of INR2,170 (from INR2,368 earlier). Based on 23% earnings CAGR expected over FY19-21E and led by healthy performance in the DF segment, enhanced margins in the US generics business, and attractive valuation, we maintain a BUY rating on the stock.
... Read more
11-Feb-19
Price @ Call: 1897
Target: 2340
BUY
11-Feb-19
Price @ Call: 1897
Target: 2365
BUY

ALKEM Share Price Target - Broker Reports - 2018

5-Nov-18
Price @ Call: 1892.69
Target: 2415
BUY
16-Aug-18
Price @ Call: 2030.33
Target: 2307
BUY
13-Aug-18
Price @ Call: 2071.2
Target: 2410
BUY
13-Aug-18
Price @ Call: 2071.2
Target: 2475
BUY
31-May-18
Price @ Call: 1938.05
Target: 2400
BUY
16-Feb-18
Price @ Call: 2163.83
Target: 2500
BUY
10-Feb-18
Price @ Call: 2154.79
Target: 2500
BUY
31-Jan-18
Price @ Call: 2246
Target: 2610
BUY
4-Jan-18
Price @ Call: 2185
Target: 2341
BUY

ALKEM Share Price Target - Broker Reports - 2017

28-Nov-17
Price @ Call: 1964.36
Target: 2500
BUY
20-Nov-17
Price @ Call: 1967
Target: 2150
BUY
9-Oct-17
Price @ Call: 1875.75
Target: 2079
BUY
21-Aug-17
Price @ Call: 1793
Target: 2000
BUY
22-Jun-17
Price @ Call: 1870.25
Target: 2161
BUY
6-Jun-17
Price @ Call: 1933.81
Target: 2100
BUY
10-Feb-17
Price @ Call: 1830
Target: 2150
BUY
16-Feb-17
Price @ Call: 1985.37
Target: 2100
BUY
3-Jan-17
Price @ Call: 1620
Target: 1989
BUY

ALKEM Share Price Target - Broker Reports - 2016

15-Sep-16
Price @ Call: 1614
Target: 1800
BUY
18-Aug-16
Price @ Call: 1543.9
Target: 1800
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • ALKEM Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 33,189.87
    Upside Target 23,081.93
    Upside Target 13,006.62
    Pivot2,898.68
    Downside Target 12,823.37
    Downside Target 22,715.43
    Downside Target 32,640.12
  • ALKEM Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 33,085.18
    Upside Target 22,901.77
    Upside Target 12,781.93
    Pivot2,598.52
    Downside Target 12,478.68
    Downside Target 22,295.27
    Downside Target 32,175.43
  • ALKEM Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 33,205.32
    Upside Target 22,961.83
    Upside Target 12,811.97
    Pivot2,568.48
    Downside Target 12,418.62
    Downside Target 22,175.13
    Downside Target 32,025.27
  • ALKEM Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 33,081.93
    Upside Target 23,011.93
    Upside Target 12,968.68
    Pivot2,898.68
    Downside Target 12,828.68
    Downside Target 22,785.43
    Downside Target 32,715.43
  • ALKEM Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,901.77
    Upside Target 22,785.93
    Upside Target 12,714.36
    Pivot2,598.52
    Downside Target 12,482.68
    Downside Target 22,411.11
    Downside Target 32,295.27
  • ALKEM Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 32,961.83
    Upside Target 22,811.57
    Upside Target 12,718.74
    Pivot2,568.48
    Downside Target 12,418.22
    Downside Target 22,325.39
    Downside Target 32,175.13
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020